Liquid biopsy has entirely revolutionized the field of clinical oncology, providing easier tumor sampling, continuous monitoring through repeated sampling, and developing personalized therapeutic strategies. Liquid biopsy consists of isolating tumor-derived entities like circulating tumor cells (CTCs), circulating extracellular nucleic acids (cell-free DNA, cfDNA; or cell-free RNA, cfRNA), extracellular vesicles, etc., present in the body fluids of patients with cancer, followed by an analysis of genomic and proteomic data contained within them. RNA in cells has a wide variety of functions and is generally divided into coding RNA (such as mRNA) and non-coding RNA (ncRNA) based on the coding capability for proteins. In addition to mRNA, ncRNA includes many types, such as tRNA and rRNA, small interfering RNA (siRNA), microRNA (miRNA), PIWI-interacting RNA (piRNA), long non-coding RNA (lncRNA), circular RNA (circRNA), etc. Accumulating evidence in the past decades indicates that ncRNA plays a critical role in the pathogenesis of various types of cancer.
This research topic aims to explore the novel roles of both coding RNA and ncRNA from body liquids in diagnostic, therapeutic, and prognostic applications in patients with cancer.
We focus on RNA molecules with physiological and pathological implications in tumorigenesis and the progression of different types of cancers. In particular, the clinical role of ncRNA in cancer liquid biopsy is featured. However, papers that include only bioinformatic analysis without local validation are not featured.
We will especially welcome Original Research, Review, and Perspective, including (but not limited to) the following areas:
• Circulating RNA as a biomarker in early diagnosis of cancer
• Therapeutic and prognostic roles of RNA in cancer
• RNA in extracellular vesicles in cancer
• RNA profiling in cancer liquid biopsy
• New methods or technologies for cfRNA analysis
Topic Editor Tao Li served as the Principal Investigator of the HEALTH Biomedical R&D Center. All other Topic Editors declare no competing interests with regards to the Research Topic subject.
Liquid biopsy has entirely revolutionized the field of clinical oncology, providing easier tumor sampling, continuous monitoring through repeated sampling, and developing personalized therapeutic strategies. Liquid biopsy consists of isolating tumor-derived entities like circulating tumor cells (CTCs), circulating extracellular nucleic acids (cell-free DNA, cfDNA; or cell-free RNA, cfRNA), extracellular vesicles, etc., present in the body fluids of patients with cancer, followed by an analysis of genomic and proteomic data contained within them. RNA in cells has a wide variety of functions and is generally divided into coding RNA (such as mRNA) and non-coding RNA (ncRNA) based on the coding capability for proteins. In addition to mRNA, ncRNA includes many types, such as tRNA and rRNA, small interfering RNA (siRNA), microRNA (miRNA), PIWI-interacting RNA (piRNA), long non-coding RNA (lncRNA), circular RNA (circRNA), etc. Accumulating evidence in the past decades indicates that ncRNA plays a critical role in the pathogenesis of various types of cancer.
This research topic aims to explore the novel roles of both coding RNA and ncRNA from body liquids in diagnostic, therapeutic, and prognostic applications in patients with cancer.
We focus on RNA molecules with physiological and pathological implications in tumorigenesis and the progression of different types of cancers. In particular, the clinical role of ncRNA in cancer liquid biopsy is featured. However, papers that include only bioinformatic analysis without local validation are not featured.
We will especially welcome Original Research, Review, and Perspective, including (but not limited to) the following areas:
• Circulating RNA as a biomarker in early diagnosis of cancer
• Therapeutic and prognostic roles of RNA in cancer
• RNA in extracellular vesicles in cancer
• RNA profiling in cancer liquid biopsy
• New methods or technologies for cfRNA analysis
Topic Editor Tao Li served as the Principal Investigator of the HEALTH Biomedical R&D Center. All other Topic Editors declare no competing interests with regards to the Research Topic subject.
